Fenwick Represents Sema4 in Agreement to Acquire GeneDx

Fenwick represented Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, in its agreement to acquire GeneDx, an OPKO Health subsidiary focused on genomic testing and analysis, and related $200 million PIPE financing.

More information can be obtained from Sema4’s announcement.

Fenwick has represented Sema4 in all of its financing transactions, as well as its 2021 de-SPAC merger with CM Life Sciences, Inc.

The Fenwick transaction team includes corporate partners Ethan Skerry, Per Chilstrom and Michael Pilo; associates Victoria Lupu, Steven Jean, Kristen Nicol, Benjamin Bertan and Corinne Nhaissi and law clerk Philip Ewing; executive compensation & employee benefits partner Matthew Cantor, counsel Laura McIntyre and associate Jennifer Lin; technology transactions partner Stefano Quintini, counsel Ana Razmazma and associates Pinar Bailey, Kehl Sink and Aaron Dunn; regulatory partner Steve Albertson and associate Kaylynn Noethlich; and tax partner David Forst and associate Alexis Maguina.